EquityFlow
›
Companies
› Vesper Bio
Vesper Bio
Biotech
· Copenhagen, DK
Oral small-molecule sortilin inhibitors for CNS diseases
Funding history
Date
Round
Amount
Jan 2024
Grant
Copenhagen biotech Vesper Bio secured a ~$873K grant from The Michael J. Fox Foundation to study its sortilin inhibitors in Parkinson's disease.
$873K
Investors
The Michael J. Fox Foundation
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →